Description

4-(3-Chloro-4-Fluorophenylamino)-7-Methoxy-6-[3-(4-Morpholinyl)Propoxy]Quinazoline Dihydrochloride is a high-purity, small molecule pharmaceutical intermediate and research chemical of significant importance in medicinal chemistry. This compound is a key building block in the synthesis of advanced kinase inhibitors, which are crucial for targeted cancer therapies and other disease-modifying treatments. It is primarily required by pharmaceutical R&D laboratories, contract research organizations (CROs), and fine chemical manufacturers engaged in the development of novel therapeutic agents.

Application

• Pharmaceutical Intermediate: A critical precursor in the multi-step synthesis of potent and selective kinase inhibitors for oncology research.
• Biochemical Research: Used as a reference standard and active compound in in vitro assays to study enzyme inhibition, cellular signaling pathways, and mechanism of action.
• Preclinical Development: Serves as a starting material for the preparation of candidate drug molecules for pharmacokinetic, pharmacodynamic, and toxicology studies.
• Academic Research: Employed in university and institutional labs for fundamental research into structure-activity relationships (SAR) of quinazoline-based compounds.
• Process Chemistry: Utilized for scaling up synthetic routes and optimizing manufacturing processes for Active Pharmaceutical Ingredients (APIs).
• Custom Synthesis: A base compound for the custom synthesis of novel analogs and derivatives for proprietary drug discovery programs.

Basic Information

Item	Details
Product Name	4-(3-Chloro-4-Fluorophenylamino)-7-Methoxy-6-[3-(4-Morpholinyl)Propoxy]Quinazoline Dihydrochloride
CAS No.	184475-56-7
Molecular Formula	C22H25ClF N5O3 • 2HCl
Molecular Weight	523.83 g/mol (Free base: 453.92 g/mol)
Synonyms	N-(3-Chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholinyl)propoxy]-4-quinazolinamine dihydrochloride; 4-Quinazolinamine, N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholinyl)propoxy]-, dihydrochloride; GW 572016 Dihydrochloride (Lapatinib Intermediate); Lapatinib Ditosylate Intermediate; Tykerb Intermediate; EGFR/ErbB-2 Inhibitor Intermediate
EINECS	Contact for details

Quality Control

Our 4-(3-Chloro-4-Fluorophenylamino)-7-Methoxy-6-[3-(4-Morpholinyl)Propoxy]Quinazoline Dihydrochloride is manufactured under strict quality management systems. Every batch undergoes rigorous analytical testing, including HPLC for purity and identity confirmation (IR, NMR), to ensure it meets the high standards required for pharmaceutical research and development. A comprehensive Certificate of Analysis (COA) detailing purity, assay, and impurity profiles is provided with each shipment and is available upon request.

Storage

Preserve in a tightly closed container, protected from light. Store in a cool, dry place at a controlled room temperature (15-25°C). This compound is hygroscopic (moisture-sensitive) and should be handled in a dry environment to prevent degradation. For long-term storage, consider desiccated conditions.

Specification

Item	Specification
Appearance	White to off-white powder
Identification (IR)	Conforms to structure
Identification (HPLC)	Retention time matches reference standard
Purity (HPLC)	≥ 98.0%
Assay (Titration)	97.0% - 103.0% (on anhydrous basis)
Water Content (KF)	≤ 2.0%
Residue on Ignition	≤ 0.5%
Heavy Metals	≤ 20 ppm

Note: Specifications can be tailored. Please contact us for the detailed technical data sheet of a specific grade.